Xiaoyun Li

Active 2001–2026

Also published as
XiaoYun Li
335
Papers
24,904
Citations
68
h-index
227
i10-index

Citations

Citations per year for Xiaoyun Li2000: 2 citations2004: 1 citations2005: 1 citations2006: 1 citations2008: 4 citations2009: 2 citations2010: 6 citations2011: 5 citations2012: 16 citations2013: 52 citations2014: 175 citations2015: 364 citations2016: 447 citations2017: 507 citations2018: 416 citations2019: 909 citations2020: 1,070 citations2021: 1,153 citations2022: 1,115 citations2023: 962 citations2024: 1,573 citations2025: 1,100 citations2026: 115 citations2001–2003: no citations, so these years are not shown2007: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 3,787 citing papers, 28.3% of this breakdownUnited States: 2,866 citing papers, 21.4% of this breakdownUnited Kingdom: 511 citing papers, 3.8% of this breakdownGermany: 497 citing papers, 3.7% of this breakdownFrance: 464 citing papers, 3.5% of this breakdownItaly: 447 citing papers, 3.3% of this breakdownAustralia: 387 citing papers, 2.9% of this breakdownCanada: 382 citing papers, 2.9% of this breakdownJapan: 312 citing papers, 2.3% of this breakdownSpain: 271 citing papers, 2% of this breakdownIndia: 261 citing papers, 1.9% of this breakdownNetherlands: 251 citing papers, 1.9% of this breakdown
0%28.3%Other 22.1%

Fields

  • Medicine48%
  • Biochemistry, Genetics and Molecular Biology18.9%
  • Immunology and Microbiology9.9%
  • Computer Science8.2%
  • Engineering5.3%
  • Materials Science2.5%
  • Other7.2%

Topics

  • Cancer Immunotherapy and Biomarkers10.4%
  • Immunotherapy and Immune Responses4.4%
  • CAR-T cell therapy research3.9%
  • Immune cells in cancer3.3%
  • Immune Cell Function and Interaction2.7%
  • Melanoma and MAPK Pathways1.5%
  • Other73.8%

Coauthors

All papers

Open in search
  1. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming

    Authors: , , , , , , , , , , , , , , , , - Nature Immunology 2017 cited by 1,185

  2. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

    Authors: , , , , , - Nature Reviews Clinical Oncology 2019 cited by 783

  3. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions

    Authors: , , , , , , , , , , , - Nature Immunology 2023 cited by 210

  4. Nezha: Interpretable Fine-Grained Root Causes Analysis for Microservices on Multi-modal Observability Data

    Authors: , , , , , - Joint European Software Engineering Conference and Symposium on the Foundations of Software Engineering, ESEC/SIGSOFT FSE 2023 cited by 95

  5. MicroRank: End-to-End Latency Issue Localization with Extended Spectrum Analysis in Microservice Environments

    Authors: , , , , , , , , - Web Conference 2021, WWW 2021 cited by 114

  6. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 3,395

  7. Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity

    Authors: , , , , , , , , , , , , , , , , , , - Nature Immunology 2021 cited by 207

  8. A Spatiotemporal Deep Learning Approach for Unsupervised Anomaly Detection in Cloud Systems

    Authors: , , , , , , , - IEEE Transactions on Neural Networks and Learning Systems, IEEE Trans. Neural Networks Learn. Syst. 2020 cited by 140

  9. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2016 cited by 1,062

  10. SwissLog: Robust and Unified Deep Learning Based Log Anomaly Detection for Diverse Faults

    Authors: , , , , - IEEE 31st International Symposium on Software Reliability Engineering (ISSRE) 2020 cited by 137

  11. A genomic and epigenomic atlas of prostate cancer in Asian populations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bijun Lian, Xiaoyun Li, Yun Zhang, Chao Wang, Yue Wang, Guangan Xiao, Junfeng Jiang, Yue Yang, Chang Yin Liang, Jianquan Hou, Jianquan Hou, Ming Chen, Ning Jiang, Dahong Zhang, Song Wu, Jinjian Yang, Tao Wang, Yongliang Chen, Jiantong Cai, Wenzeng Yang, Jun Xu, Shaogang Wang, Xu Gao, Ting Wang, Yinghao Sun, Xu Gao, Ting Wang, Ting Wang, Yinghao Sun - Nature 2020 cited by 355

  12. SwissLog: Robust Anomaly Detection and Localization for Interleaved Unstructured Logs

    Authors: , , , , - IEEE Transactions on Dependable and Secure Computing, IEEE Trans. Dependable Secur. Comput. 2022 cited by 69

  13. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 cited by 1,564

  14. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 794

  15. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 678

  16. Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 cited by 218

  17. Sprayable and self-healing chitosan-based hydrogels for promoting healing of infected wound via anti-bacteria, anti-inflammation and angiogenesis

    Authors: , , , , , - Carbohydrate Polymers 2024 cited by 94

  18. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2014 cited by 1,761

  19. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma

    Authors: , , , , , , , , , , , , , , , , - Cell Death and Differentiation 2022 cited by 150

  20. Incidence and risk factors of drug‐induced liver injury

    Authors: , , - Liver International 2022 cited by 153

  21. Collagen fibril-like injectable hydrogels from self-assembled nanoparticles for promoting wound healing

    Authors: , , , , , , , , , , , - Bioactive Materials 2023 cited by 78

  22. Immunoediting instructs tumor metabolic reprogramming to support immune evasion

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cell Metabolism 2023 cited by 100

  23. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jun Zhang, Su‐Mei Cao - Annals of Oncology 2019 cited by 166

  24. Herbal decoctosome is a novel form of medicine

    Authors: , , , , , , , , , , , , , , , , - Science China Life Sciences 2019 cited by 102